§989.1. Unlawful production, manufacture, distribution, or possession of hallucinogenic
plants; exceptions
A.(1) It shall be unlawful for any person knowingly or intentionally to produce,
manufacture, distribute, or possess with intent to produce, manufacture, or distribute a
material, compound, mixture, or preparation intended for human consumption which
contains a hallucinogenic plant.
(2) Whoever violates the provisions of this Subsection shall be sentenced to a term
of imprisonment with or without hard labor for not less than two years nor more than ten
years and may, in addition, be sentenced to pay a fine of not more than twenty thousand
dollars.
B.(1) It shall be unlawful for any person knowingly or intentionally to possess a
material, compound, mixture, or preparation intended for human consumption which
contains a hallucinogenic plant.
(2) Any person who violates the provisions of this Subsection shall be sentenced to
a term of imprisonment with or without hard labor for not more than five years and may, in
addition, be sentenced to pay a fine of not more than five thousand dollars.
C. For the purposes of this Section:
(1) "Distribute" means to sell, lease, rent, barter, trade, furnish, supply, or otherwise
transfer in exchange for anything of value a material, compound, mixture, or preparation
intended for human consumption which contains a hallucinogenic plant.
(2) "Hallucinogenic plant" means any part or portion of any of the following:
(a) Brugmansia arborea.
(b) Amanita muscaria.
(c) Conocybe spp.
(d) Panaeolus spp.
(e) Psilocybe spp.
(f) Stropharia spp.
(g) Vinca rosea.
(h) Ipomoea violacea.
(i) Datura spp.
(j) Pancreatium trianthum.
(k) Kaempferia galanga.
(l) Olmedioperebea sclerophylla.
(m) Mesembryanthemum spp.
(n) Virola spp.
(o) Anadenanthera peregrina.
(p) Anadenanthera colubrina.
(q) Erythina spp.
(r) Genista canariensis.
(s) Mimosa hostilis.
(t) Rhynchosia spp.
(u) Sophora secundiflora.
(v) Peganum harmala.
(w) Banisteriopsis spp.
(x) Tetrapteris methystica.
(y) Heimia salicfolia.
(z) Tabernanthe iboga.
(aa) Prestonia amazonica.
(bb) Lagoehilus inebrians.
(cc) Rivea corymbosa.
(dd) Salvia divinorum.
(ee) Atropa belladonna.
(ff) Hyoscyamus niger.
(gg) Mandragora officinarum.
(hh) Brunfelsia spp.
(ii) Methysticodendron amesianum.
(jj) Latua pubiflora.
(kk) Calea Zacatechichi.
(ll) Physalis subglabrata.
(mm) Solanum carolinense.
(nn) Amanita pantherina.
(3) "Homeopathic drug" means any drug labeled as being homeopathic which is
listed in the Homeopathic Pharmacopeia of the United States, an addendum to it, or its
supplements. The potencies of homeopathic drugs are specified in terms of dilution.
Homeopathic drug products must contain diluents commonly used in homeopathic
pharmaceutics. Drug products containing homeopathic ingredients in combination with non-homeopathic active ingredients are not homeopathic drug products.
(4) "Manufacture" means the production, preparation, propagation, compounding,
or processing of a material, compound, mixture, or preparation intended for human
consumption which contains a hallucinogenic plant either directly or indirectly by extraction
from substances of natural origin, or independently by means of chemical synthesis, or by
a combination of extraction and chemical synthesis. Manufacturer includes any person who
packages, repackages, or labels any container holding a material, compound, mixture, or
preparation intended for human consumption which contains a hallucinogenic plant.
(5) "Production" includes the manufacture, planting, cultivation, growing, or
harvesting of a hallucinogenic plant.
D. The provisions of this Section shall not apply to the possession, planting,
cultivation, growing, or harvesting of a hallucinogenic plant strictly for aesthetic,
landscaping, or decorative purposes.
E. The provisions of this Section shall not apply to any dosage form which is legally
obtainable from a retail establishment without a prescription and is recognized by the Federal
Food and Drug Administration as a homeopathic drug.
F. The provisions of this Section shall not apply to any dosage form which is labeled
as a dietary supplement and is manufactured in compliance with the requirements of sections
402(g)(2), 415, and 761 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 342(g)(2),
350d, and 379aa-1).
Acts 2005, No. 159, §1; Acts 2015, No. 373, §1, eff. July 1, 2015; Acts 2018, No.
206, §4; Acts 2023, No. 201, §1.